Get started
Cue Biopharma, Inc.Cue Biopharma, Inc.Cue Biopharma, Inc.

Cue Biopharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

CUE chart


Full chart

CUE upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪63.02 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.7493 USD
Net income (FY)
‪−40.67 M‬ USD
Revenue (FY)
‪9.29 M‬ USD
Shares float
‪74.78 M‬
Beta (1Y)
1.90

Employees


Employees (FY)
41
Change (1Y)
−12 −22.64%
Revenue / Employee (1Y)
‪226.51 K‬ USD
Net income / Employee (1Y)
‪−992.05 K‬ USD

About Cue Biopharma, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Daniel R. Passeri
Website
cuebiopharma.com
Headquarters
Boston
Founded
2014
FIGI
BBG00FVMPFN7
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CUE news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as CUE.

Frequently Asked Questions


The current price of CUE is 0.8566 USD — it has increased by 6.85% in the past 24 hours. Watch Cue Biopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cue Biopharma, Inc. stocks are traded under the ticker CUE.
CUE stock has risen by 7.22% compared to the previous week, the month change is a −17.20% fall, over the last year Cue Biopharma, Inc. has showed a −44.01% decrease.
We've gathered analysts' opinions on Cue Biopharma, Inc. future price: according to them, CUE price has a max estimate of 6.00 USD and a min estimate of 2.00 USD. Watch CUE chart and read a more detailed Cue Biopharma, Inc. stock forecast: see what analysts think of Cue Biopharma, Inc. and suggest that you do with its stocks.
CUE reached its all-time high on May 26, 2020 with the price of 31.6900 USD, and its all-time low was 0.4500 USD and was reached on Sep 24, 2024. View more price dynamics on CUE chart.
See other stocks reaching their highest and lowest prices.
CUE stock is 7.49% volatile and has beta coefficient of 1.90. Track Cue Biopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cue Biopharma, Inc. there?
Today Cue Biopharma, Inc. has the market capitalization of ‪63.02 M‬, it has increased by 21.24% over the last week.
Yes, you can track Cue Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Cue Biopharma, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
CUE earnings for the last quarter are −0.13 USD per share, whereas the estimation was −0.086 USD resulting in a −51.16% surprise. The estimated earnings for the next quarter are −0.15 USD per share. See more details about Cue Biopharma, Inc. earnings.
Cue Biopharma, Inc. revenue for the last quarter amounts to ‪1.58 M‬ USD, despite the estimated figure of ‪1.70 M‬ USD. In the next quarter, revenue is expected to reach ‪1.27 M‬ USD.
CUE net income for the last quarter is ‪−9.50 M‬ USD, while the quarter before that showed ‪−8.66 M‬ USD of net income which accounts for −9.65% change. Track more Cue Biopharma, Inc. financial stats to get the full picture.
No, CUE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 41 employees. See our rating of the largest employees — is Cue Biopharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cue Biopharma, Inc. EBITDA is ‪−39.24 M‬ USD, and current EBITDA margin is −422.56%. See more stats in Cue Biopharma, Inc. financial statements.
Like other stocks, CUE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cue Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cue Biopharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cue Biopharma, Inc. stock shows the sell signal. See more of Cue Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.